OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 211 - 220 of 742 studies

Cancer and neoplasms

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a Phase 3, randomized, controlled, multicenter, open-label study to evaluate the efficacy of IMC-F106C + nivolumab compared with nivolumab regimens in HLA-A*02:01-positive adult participants with previously untreated advanced (unresectable or metastatic) melanoma. Participants will be randomized 1:1:1 to IMC-F106C 40 mcg + nivolumab (Arm A), IMC-F106C 160 mcg + nivolumab (Arm B), or a nivolumab regimen (Arm C). The control Arm C will be country-specific and include: • Nivolumab + relatlimab, an emerging SoC, in countries where this combination ...

GO TO STUDY Go

Cancer and neoplasms

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) in combination with Durvalumab compared with Pembrolizumab in combination with Investigator’s Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel/Gemcitabine+Carboplatin) in Patients with PDL1 positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

cases in 2020 globally (11.7% of all new cancers). Breast cancer is also the fifth most common cause of death from cancer, with an estimated 685000 deaths in 2020 (Sung et al 2021). Despite advances in the diagnosis and treatment of breast cancer, around 5% to 10% of women diagnosed with breast cancer have metastatic disease at the time of diagnosis, with a much higher percentage in low- and middle-income countries, and up to 30% of women with early-stage non-metastatic ...

GO TO STUDY Go

Generic health relevance Reproductive health and childbirth

The Generation Study

Each year in England, about 3,000 babies are born with one of about 200 genetic conditions that are treatable in early childhood. Nine of these conditions are currently looked for in the NHS newborn bloodspot test. But there are many more conditions where earlier diagnosis and treatment could help. This study investigates the genomes of newborn babies to see if we can find and treat rare genetic conditions early. A genome is a person’s entire genetic sequence ...

GO TO STUDY Go

Cardiovascular

The Metformin Aneurysm Trial (MAT) An investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial to determine the effect of metformin on abdominal aortic aneurysm (AAA) associated events, including AAA repair and AAA mortality (due to aneurysm rupture). (UK MAT)

MAT is an international,multicenter,prospective,parallel-group,randomised,double-blind,placebo-controlled trial. The double-blind period will be preceded by a 6-week,single-blind (participants will remain blind),active run-in phase in which all potential participants will receive metformin sustained release (SR) with fortnightly dose increments. The aim of this run-in phase is to ensure the randomisation of participants who tolerate the treatment regimen and to increase the likelihood of high treatment adherence during long term follow-up. Randomised participants will receive study medication for an average of 3.5 years (up to ...

GO TO STUDY Go

Oral and Gastrointestinal

CirrhoCare, A real-world, randomised controlled study, to determine the clinical and cost-effectiveness of CirrhoCare digital home monitoring and management in patients with decompensated cirrhosis

Cirrhosis, progressive scaring of the liver- has many causes, principally, excessive alcohol intake, fatty-liver and viral infections. Unlike many chronic diseases, cirrhosis deaths are increasing rapidly year-on-year. It is the third commonest cause of premature, UK working-age deaths, with 62,000 years of working-life lost each year and NHS care costs of £4.53bn annually. One quarter of all UK cirrhosis patients are at-risk of acute decompensation, whereby complications such as fluid-overload, confusion and infections arise, requiring hospital-emergency treatment. Currently, decompensated cirrhosis patients ...

GO TO STUDY Go

Inflammatory and immune system

Steroid TreAtment tRial in JIA: A randomised trial to compare effectiveness, safety and cost-effectiveness of intravenous versus oral corticosteroid induction regimens for children and young people with juvenile idiopathic arthritis. (STAR-JIA)

Juvenile Idiopathic Arthritis (JIA) is a chronic inflammatory disease affecting 1 in 1000 children with around 12,000 children with JIA in England and Wales [1,2]. Delay in diagnosis and under-treatment lead to joint damage,disability and reduced quality of life [3]. In the UK and most of the world,children and young people with new-onset poly-articular Juvenile Idiopathic Arthritis (pcJIA) are commenced on corticosteroids and methotrexate [2,4,5]. As methotrexate can take several months to have an effect,corticosteroids are used to rapidly control ...

GO TO STUDY Go

Infection

Breathing Assistance in CHildren with bronchiolitis (BACHb): a group-sequential two-stratum multicentre open-label randomised clinical trial of respiratory support in infants with acute bronchiolitis

Nearly 30,000 infants under one are admitted to hospitals in England each year with bronchiolitis, a common viral chest infection. Half of them need oxygen treatment through ‘nasal cannula’ (thin tubes inserted into the nostrils). Most infants respond to nasal cannula oxygen alone, but some need additional breathing support. In these infants, different treatments such as ‘humidified’ (moist) standard oxygen (HSO), high-flow nasal cannula (HFNC) and ‘CPAP’ (pressurised oxygen delivered through the nose) are used. However, it is not clear ...

GO TO STUDY Go

Cardiovascular

Randomised comparison of the clinical Outcome of single versus Multiple Arterial grafts (ROMA)

A coronary artery bypass graft (CABG) is a surgical procedure used to treat coronary heart disease. It diverts blood around narrowed or clogged parts of the major arteries to improve blood flow and oxygen supply to the heart. Like all organs in the body, the heart needs a constant supply of blood which comes through arteries called coronaries. Over time, these arteries can become narrowed and hardened by the build-up of fatty deposits called atherosclerosis plaques. CABG involves taking a blood ...

GO TO STUDY Go

Generic health relevance

How might Physician Associates help (or not) address the workforce crisis in the NHS

Our overall research question is: How might Physician Associates help (or not) address the workforce crisis in the NHS and more particularly are they part of the solution in NHS hospitals? This will be a multiple methods study including five activities. • Activity a: Secondary NHS workforce database analysis where we analyse secondary data analysis from publicly available database,Electronic Staff Records (ESR) and NHS trust and health board HR database Our main objectives for activity A are to (1) explore available administrative ...

GO TO STUDY Go

Skin

A phase IV, multi-arm muti-stage, assessor blind randomised control trial comparing the effectiveness, tolerability and cost effectiveness of systemic treatments for adults with moderate-severe atopic eczema (BEACON)

BEACON is a UK based,multicentre,1 year,assessor-blind,parallel group,superiority,randomised controlled trial. The primary aim of the trial is to determine the effectiveness of methotrexate and dupilumab compared with ciclosporin. The primary endpoint is change in objective disease severity at 6 months,presented as mean absolute change from baseline,using the Eczema Area Severity Index (EASI,blinded assessment). Patients will be randomised 1:1:1 to methotrexate,dupilumab or ciclosporin for 6 months (optional dose increase at 3 months for those on methotrexate or ciclosporin as per clinical practice). ...

GO TO STUDY Go